Navigation Links
Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance

Athletes Using Surgex(TM) can be Assured of No Banned Substances

BASKING RIDGE, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), announced today that Surgex(TM) ( has been tested and certified into the Banned Substance Control Group's (BSCG) certification program. This is the only certification program in the US that uses a World Anti Doping Agency accredited laboratory to detect for dangerous banned substances in nutritional supplements. Each batch of Millennium's line of Surgex(TM) products are now tested and certified not to contain substances such as hormones, steroids, stimulants, diuretics, etc that are banned for Professional, Collegiate and Olympic sports. The BSCG certification in addition to the Surgex'(TM) clinical trials should provide the product a competitive advantage upon commercialization into the billion dollar sports nutritional supplement marketplace.

"The athlete can now be assured that our Surgex(TM) line of products can be safely consumed as each batch is tested for a list of substances that are banned by organizations such as the International Olympic Committee (IOC), the World Anti-Doping Agency (WADA), the United States Anti-Doping Agency (USADA), the National Collegiate Athletic Association (NCAA), the National Football League (NFL), and many other professional and amateur sports leagues." states Carl Germano, RD, CNS, CDN, clinical nutritionist and VP of Research & product Development for Millennium Biotechnologies.

With over 5 years in the medical market as a nutritional adjunct to medical care for immuno-compromised conditions and several successful studies including 2 double blind, placebo controlled trials in Division 1 athletes, the Surgex(TM) line of products is breaking new ground for credibility and professionalism in the sports nutrition sector.

The final set of results from Millennium's sponsored Division 1 Football trial at Rutgers University have shown that Surgex(TM) had a significant effect on recovery markers including testosterone:cortisol ratios compared to a market leading sports beverage on the market. "Along with our previous statistically significant improvements in body composition and strength parameters, the recovery marker data continues to validate Surgex(TM) as an important nutritional adjunct for the athlete" states Mr. Germano. "As we have seen in the medical market, Surgex is now able to offer the athlete a product that will assist in recovery in efforts to improve performance. In addition, our participation in the BSCG program continues to set us apart from the competition."

The continued usage and acceptability of Surgex(TM) by Professional, Olympic, and Collegiate athletes is providing the valuable market information which will allow Millennium to develop the best strategy to commercialize Surgex(TM), expected in Q3 of 2008.

About Surgex(TM):

Surgex(TM) ( was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States The proprietary Surgex(TM) formula intends to meet the growing demand of elite level Professional, Olympic and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab Surgex(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as the lessening of free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified by The Banned Substances Control Group (BSCG) to contain no banned substances.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(TM) sports nutrition formula, clinically proven to address the nutritional concerns of the Professional, Olympic and amateur elite athletes. These athletes often experience similar symptoms post- workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and Surgex(TM) are not intended to diagnose, treat, cure, or prevent and disease.

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
4. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
5. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 --> ... "Spine Biologics Market by Product Type (Bone Graft, Bine Graft ... and Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography ... market was valued at $1.90 Billion in 2014 and is ... of 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical Devices ... pleased to announce the appointment of Anders Jonzon ... Dr. Jonzon is ... at Children,s Hospital, Uppsala University, Uppsala and Children,s Hospital, ... he was a fellow at the Cardiovascular Institute (UCSF). ...
(Date:11/24/2015)... 2015 . ... adds Latest Guidebook for Chinese Medical Device GMP ... in November 2015 to the medical devices market ... at . China ... global economies with a fifth population in the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Students and ... were awarded to winners of the Create Real Impact awards. California Casualty ... to help stem the tide of distracted and reckless driving, the number one killer ...
(Date:11/24/2015)... ... 25, 2015 , ... Genesis Chiropractic Software helps practice owners ... agreement between the practice owner and the patient that automatically manages all five ... Click here to learn more. , According to Dr. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Dr. Todd ... now offer laser services to many of his patients. Dr. Afferica now uses the ... to reduce the amount of time the doctor uses other traditional cutting tools, such ...
Breaking Medicine News(10 mins):